Although one patient treated with Ocrevus has reportedly developed PML, Roche blamed this on previous treatment with Tysabri. And while Biogen’s Tecfidera (dimethyl fumarate) pill is also ...

If any of the following medical conditions or other health factors are relevant to you, talk with your doctor before receiving Tysabri: Ocrevus is also approved to treat primary progressive MS ...

We expect steeper Tysabri declines beginning in 2024, following the launch of a Sandoz biosimilar. Our assumption on Ocrevus royalties are based on peak sales of $9 billion. For Spinraza ...

The FDA has approved three such drugs for MS. Ocrelizumab (Ocrevus) treats relapsing forms of MS, including: Clinically isolated syndrome Relapsing-remitting MS Active secondary progressive MS in ...

Although one patient treated with Ocrevus has reportedly developed PML, Roche blamed this on previous treatment with Tysabri. Gavin Giovannoni, professor of Neurology at Barts and The London ...

Moreover, high-efficacy monoclonal antibody therapy -- ocrelizumab (Ocrevus), rituximab (Rituxan), or natalizumab (Tysabri) - ...

Ocrelizumab (Ocrevus), is a drug that sticks to B cells and destroys them. That helps prevent MS damage and symptoms. It’s approved by the FDA for: Clinically isolated syndrome Relapsing ...

Research suggests that Kesimpta is as effective as other monoclonal antibodies, including Ocrevus and Tysabri, in reducing MS ...

Tysabri (natalizumab) helps treat forms of multiple sclerosis and Crohn’s disease. The drug comes as an infusion solution. Tysabri is not safe to receive in pregnancy and may not be safe to ...

In September, the Swiss pharma won back-to-back FDA approvals for subcutaneous versions of its multiple sclerosis drug Ocrevus and cancer immunotherapy Tecentriq. Dubbed Ocrevus Zunovo ...

Ocrevus is a medicine commonly used to treat primary progressive MS, but it can take up to four hours to receive intravenously. A new version called “Ocrevus Zunovo” was recently approved by ...

Biogen BIIB reported third-quarter 2024 adjusted earnings per share (EPS) of $4.08, which beat the Zacks Consensus Estimate ...